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Abstract
Background: While the ability of bacteriophages to kill bacteria is well known and has been used
in some centers to combat antibiotics – resistant infections, our knowledge about phage
interactions with mammalian cells is very limited and phages have been believed to have no intrinsic
tropism for those cells.
Presentation of the hypothesis: At least some phages (e.g., T4 coliphage) express Lys-Arg-Gly
(KGD) sequence which binds β3 integrins (primarily αIIbβ3). Therefore, phages could bind β3+
cells (platelets, monocytes, some lymphocytes and some neoplastic cells) and downregulate
activities of those cells by inhibiting integrin functions.
Testing the hypothesis: Binding of KGD+ phages to β3 integrin+ cells may be detected using
standard techniques involving phage – mediated bacterial lysis and plaque formation. Furthermore,
the binding may be visualized by electron microscopy and fluorescence using labelled phages.
Binding specificity can be confirmed with the aid of specific blocking peptides and monoclonal
antibodies. In vivo effects of phage – cell interactions may be assessed by examining the possible
biological effects of β3 blockade (e.g., anti-metastatic activity).
Implication of the hypothesis: If, indeed, phages can modify functions of β3+ cells (platelets,
monocytes, lymphocytes, cancer cells) they could be important biological response modifiers
regulating migration and activities of those cells. Such novel understanding of their role could open
novel perspectives in their potential use in treatment of cardiovascular and autoimmune disease,
graft rejection and cancer.
Background
Bacterial predators, i.e. bacteriophages (phages) – viruses
that infect and rapidly destroy bacteria, were discovered
almost a century ago and there have been many attempts
to apply phages in treating bacterial infections. While
phage treatment has been successfully used in Russia,
Georgia and Poland, it has been largely ignored in the
West. The emerging crisis of antibiotic resistance and the
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uncertain outlook for new antibiotics have dramatically
altered this state of affairs, generating renewed interest in
phages as a means of eradicating drug-resistant patho-
gens. Recently, Science published a comprehensive over-
view of the current situation and perspectives of phage
therapy, highlighting the significance of our Institute's
contributions [1].
While the ability of phages to attack bacteria has been
known since their discovery (also reflected in their name),
our knowledge about phage interactions with mammali-
an cells is very limited. In fact, phages have been believed
to have no intrinsic tropism for those cells. Such tropism
can be conferred on phages by fusing their surface pro-
teins to a cell-targeting ligand. In this way, phage vectors
have been adapted for targeted gene delivery [2]. On the
other hand, phages are the most abundant life forms on
Earth, being virtually omnipresent. Moreover, phage ther-
apy is practically free of any side effects, as shown by re-
sults of phage treatment in the former Soviet Union and
Poland (as well as in the USA, where phage preparations
were licensed for sale in 1930s) [3,4]. They are consumed
with foods, and some fresh water sources may contain up
to 109(billion) per ml [1,4]. Merril detected phages in an-
imal sera and suggested that interactions between phages
and mammalian cells should be investigated [5]. Further-
more, somatic coliphages can be detected in 68% and
B.fragilis in 11% of the stools of healthy volunteers [6],
whilst Enterococcus faecalis phages may be present in hu-
man saliva which suggest their role in the oral ecosystem
[7].
Since phages are ubiquitous in our environment, the
question arises whether human body can recognize them
and mount an immune response. Indeed, elevated titers
of antibodies against staphylococcal phage antigens can
be detected in some 10% of healthy individuals and 44%
patients with staph infections (in patients with acute in-
fection, a 4-fold rise in antiphage antibody titer can oc-
cur). During regression of infection, a titer fall has been
observed [8,9]. This data suggest that naturally occurring
phages can induce humoral immunity. Antiphage anti-
bodies can also be detected in the sera of patients treated
with these phages [4,10]. Furthermore, in vivo humoral re-
sponses to phage phi X174 have been used for more than
30 years in clinical immunology as a measure of T-helper
cell dependent antibody production [11–15]. In vitro,
anti-phi X174 antibody is produced by lymphocytes from
phage-immunized (but not unimmunized) subjects in the
presence of antigen [16]. No data on potential T cell me-
diated anti-phage responses are available. These observa-
tions suggest that humans can mount at least a humoral
response to phages and these appear to be innocuous (the
phage used for immunocompetence testing could be re-
peatedly administered intravenously). The latter conclu-
sion is also confirmed by the data of Wenger et al. who
studied the in vitro effects of phages on human lym-
phocytes and embryonic kidney cells [17]. The authors
found no viability or cytogenetic effects of phages in cul-
ture. It is also known that expression of eukariotic genes
incorporated into the phage genome can take place as an
effect of gene engineering (phages used as vectors for gene
delivery). For example, phage lambda was used for com-
plementation of the congenital absence of an enzyme in
human fibroblasts [18]. Many investigations on this kind
of engineered vectors have shown their ability of internal-
ization into eukariotic cells but no observations of phage
amplification or cell destruction have been described
[19]. Therefore, it appears that phages are not detrimental
to the host cells.
Can they bind to the host cells? As pointed out, both Led-
erberg and Merril were interested in a potential tropism of
phages for mammalian cells and suggested that such inter-
actions be investigated [5,20]. In fact, the preferential ac-
cumulation of phages in tumor tissues and inhibition of
tumor growth was already demonstrated in the 1940s,
and binding to neoplastic cells was confirmed later by
Kañtoch et al. from our Institute [21,22]. They also sug-
gested that T2 phages bind in vivo to guinea pig leukocytes
(but not erythrocytes) [23]. In addition, Wenger et al. sug-
gested that phages can attach to the plasma membrane of
lymphocytes [17]. These interesting and potentially rele-
vant observations were not pursued further, so the possi-
ble mechanisms responsible for the phenomena reported
have not been unraveled.
Which receptors could be used by phages to bind mam-
malian cells and contribute to the described effects? It is
known that viruses may utilize integrins (most often β3)
for their attachment to cells (HIV, HPEV1 virus as well as
hantavirus) [24–26]. Furthermore, adenovirus binding is
also mediated by that integrin, and phages engineered so
as to display the respective ligand can bind mammalian
cells using β3 [27]. Nevertheless, phages could also use
non-integrin receptors for binding to mammalian cells.
For example, it has been suggested that CD26 is closely in-
volved in HIV cell entry [28,29]. Furthermore, the non-in-
tegrin receptor DC-SIGN on dendritic cells may capture
and transmit HIV to a wide variety of receptor-positive
cells [30]. In addition, CMV envelope glycoprotein B is a
viral ligand for that receptor [31]. The same receptor was
shown to bind ebola glycoprotein and enhance infection
of macrophages and endothelial cells [32]. Recently, vi-
ruses have been shown to interact with macrophages and
lymphocytes and activate these cells using toll-like recep-
tors [33,34]. Therefore, one could expect that naturally oc-
curring phages may use similar mechanisms for possible
interactions with host cells.Medical Immunology 2003, 2 http://www.medimmunol.com/content/2/1/2
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As mentioned earlier, there might also be other recep-
tor:ligand systems enabling phage interactions with mam-
malian cells (both integrin and non-integrin). If they
indeed exist, further genomic studies could unravel these
potential mechanisms, which at the present time may
only be speculative. Therefore, we believe that the pro-
posed β3 : KGD binding interaction is currently the most
plausible phenomenon suggesting that phage binding to
the host cells may indeed occur.
Presentation of the hypothesis
If phages indeed use a cellular receptor for their attach-
ment to host cells, a suitable ligand for that receptor
should be available on the phages. In fact, a KGD (Lys-
Gly-Asp) sequence is present within the gp24 head corner
protein of at least some phages (e.g., T4). There are 55
copies of this protein expressed by each phage, 5 at each
head corner (the complete genomic sequence of the T4 phage
is available in databases (see the National Center for Bio-
technology Information: http://www.ncbi.nlm.nih.gov/
PMGifs/Genomes/phg.html). According to these data,
there is a KGD tripeptide sequence in a head corner pro-
tein. We confirmed this by a direct sequencing of gene 24
of our laboratory T4 strain (unpublished data).
This sequence is recognized by the major platelet integrin
αIIbβ3 (the receptor for fibrinogen, von Willebrand fac-
tor, and some extracellular matrix proteins) [35]. The in-
tegrin may also be expressed by monocytes, some of
which are β3+ and αvβ3+ [36]. Resting T cells are weakly
β3+, but can acquire αIIbβ3 within as soon as 1 hr follow-
ing in vitro activation (unpublished observations). Inter-
estingly, it has recently been shown that this integrin may
also be expressed by neoplastic cells, where it seems to be
associated with their increased ability to grow and form
metastasis [37,38]. Thus, our hypothesis implies that
phages can bind host cells expressing αIIbβ3 and proba-
bly  αvβ3 (an integrin having much lower affinity for
KGD) [39].
Recently, a CD40 ligand (CD40L, CD154), known to acti-
vate endothelium and stimulate inflammation, was
shown to have the KGD sequence, which allows it to bind
to αIIbβ3 and activate platelets [39]. CD40L is crucial for
T- and B-lymphocyte activation, and an interruption of
CD40-CD40L interaction has been shown to inhibit graft
rejection, autoimmune diseases, development of arterio-
sclerosis and angiogenesis [40,41]. KGD+ phages could
compete with CD40L in its binding to β3 integrins on
platelets and lymphocytes and prevent further activation
of these cells. By binding αIIbβ3 on activated T cells these
phages may coat their surface (phage opsonization), im-
pair their ability to interact with adherent cells, endothe-
lium and extracellular matrix proteins, and eventually
cause their clearance from the circulation (similar to
OKT3 monoclonal antibody and anti-lymphocyte globu-
lin treatment).
The possible phage binding to platelets, monocytoid cells
and lymphocytes may also explain why endogenous
phages exert only a weak antibacterial action in vivo,
whilst being so virulent against the same bacteria in vitro,
a paradox that has never been adequately explained [1].
On the one hand, such binding could markedly reduce
phage availability and dynamic interaction between phag-
es and their bacterial targets in vivo (but not in vitro, where
phages and bacteria confront each other directly, without
the involvement of any other cellular interactions). On
the other hand, the binding of phages to platelets, mono-
cytoid and lymphoid cells may also explain why phages
may be rapidly cleared from the blood by the spleen.
Testing the hypothesis
In vitro
Phages should bind cells expressing αIIbβ3 (and, to some
extent, αvβ3), i.e. platelets, neoplastic cells (positive for
β3), and activated T cells. This binding may be detected by
the standard technique which detects plaque-forming
units (PFU) produced by cell-bound phages lysing bacte-
ria as originally used by Bloch [21] (which further indi-
cates that different phage receptors are used for binding
bacteria and mammalian cells) or by counting PFU
formed by unbound phages present in cell-free superna-
tants. Furthermore, purified phages can be immobilized
on plastic plates and cell adhesion may be evaluated using
standard adhesion assays evaluated by ELISA. Binding
may be confirmed by electron microscopy and fluoro-
chrome-labeled phages, as recently described [42]. The
binding specificity can be confirmed using agents known
to block the function of β3 integrin (monoclonal antibod-
ies as well as RGD- and KGD-containing peptides, e.g., ep-
tifibatide (Integrilin), which contains a modified KGD
sequence and is known to be a specific αIIβ3 blocker)
[43]. In addition, platelet binding to fibrinogen may be
impaired by phages containing the KGD sequence and
thus competing with fibrinogen for αIIbβ3. Also, by a
similar mechanism, phages should impair the binding of
platelets to immobilized CD40L (competition in binding
to platelet αIIbβ3 between the phage and the CD40L KGD
sequence). Finally, the veracity of our hypothesis could
also be confirmed by "the experiment of nature", that is,
binding experiments using platelets from patients with
Glanzmann's thrombastenia, an inherited platelet disor-
der characterized by a complete lack of platelet aggrega-
tion due to a defect in the αIIbβ3 complex or to a
qualitative abnormality of this complex [44]; such plate-
lets should not be able to bind KGD+ phages (in contrast
to normal platelets).Medical Immunology 2003, 2 http://www.medimmunol.com/content/2/1/2
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In vivo
The administration of KGD+ phages may impair the
growth and metastasis of tumor cells, which can be as-
sayed using well-known systems in rodents (e.g., the effect
on the formation of pulmonary metastases in mice by the
β3+ B16 mouse melanoma cell line). In addition, platelet
function can be assessed in phage-treated animals with
the assumption that phage treatment could produce ef-
fects similar to those of platelet αIIbβ3 integrin blockers
currently in use (e.g., eptifibatide).
Implications
If, indeed, phages can bind mammalian cells and, per-
haps, affect integrin β3 functions in vivo, this could revo-
lutionize our current understanding of their biological
significance. Consequently, they could no longer be con-
sidered solely as "bacteriophages" or bacterial viruses, as
their anti-bacterial activity would only reflect one of their
possible, multifaceted actions. Thus, such data would
open completely new areas of study of the biological role
of phages. Evidently, if phages can downregulate β3 in-
tegrin function, this could offer exciting and novel per-
spectives of their use, not only as antibacterial agents
(whose efficacy could also be enhanced by blocking bind-
ing interactions), but also in the potential treatment of
cardiovascular and autoimmune disease, cancer and
transplant rejection. Phages could contribute to immuno-
surveillance against cancer by blocking β3 integrin activity
on neoplastic cells thus preventing their growth in situ (in-
duction of apoptosis?) and metastasis formation. Also, by
occupying the αvβ3 integrin receptor, phages could de-
prive neoplastic cells from growth signals provided by ex-
tracellular matrix proteins [45]. Bloch demonstrated
already in the 40th that injected phages store themselves
electively in malignant tumors and that the Erlich carcino-
ma loses a high percentage of its transplantation ability
upon phage addition [21]. Phage interactions with plate-
let β3 integrins and platelet-bound CD40L (which was re-
cently shown to bind to platelets and stabilize arterial
thrombi [39]), may produce effects similar to drugs inter-
fering with their functions (e.g., eptifibatide) and thereby
inhibit platelet hyperactivation which appears to play a
prominent role in the initiation of atherosclerosis and its
complications [46].
Of particular interest is the possible immunosuppressive
effect of KGD+ phages which may coat activated T cells by
binding to their αIIbβ3. Such phenomenon could be of
importance in the digestive tract, where the immune sys-
tem has to control the massive antigen challenge repre-
sented by the commensal bacterial flora. Some forms of
experimental colitis in mice are dependent on hyperactiv-
ity of CD4+ T cells [47]. KGD+ phages could provide local
immunosuppression and thereby prevent the develop-
ment of autoimmune colitis. Phages occupying cellular re-
ceptors could prevent infection and re-infection of those
cells (with their subsequent destruction) by pathogenic vi-
ruses using the same receptors for their cell entry. In other
words, phages could engage in "a combat zone in the viral
battlefield", as suggested by this type of reactivities at the
level of plasma membrane and HIV infection [48] and
thereby help our immune system that usually does not
prevent the re-infection but does prevent clinical disease
[49].
It is generally accepted that bacteria may be pathogenic or
probiotic; the latter can generate immune signals which
protect the human body against other pathogens [50,51].
This could be a more universal phenomenon and may
also apply to what have been termed simply bacteriophag-
es hitherto.
While further studies are needed to substantiate or dismiss
these claims, confirmation of our hypothesis that phages
bind to the mammalian cells would pave the way for ex-
citing novel studies on the true place and role of phages in
nature and their possible role in our defense against inter-
nal and external enemies.
Competing interests
The Institute has filed a patent application covering thera-
peutic use of phages in bacterial infections.
Authors contributions
AG conceived the hypothesis, designed the proposed ex-
periments and drafted the manuscript; KD, KSJ and AO
participated in conceiving the hypothesis, designing the
experiments and preparation of the manuscript; BWD, JB,
JW. and MN participated in designing the planned stud-
ies. All authors read and approved the final manuscript.
Note
Little is known of the interaction of bacteriophages with the
mammalian host, even while they are universally present to-
gether with their bacterial hosts..."
(J.Lederberg, Proc. Nat Acad Sci USA 1996, 93:3167).
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